Fludarabine as second-line therapy for B cell lymphocytic leukaemia: a technology assessment.

Health Technology Assessment

Type:

Extended Research Article Our publication formats
Authors:

Hyde C, Wake B, Bryan S, Barton P, Fry-Smith A, Davenport C, Song F
Journal:

Health Technology Assessment
Issue:

Volume: 6, Issue: 2
Published:

May 2002
Citation:

Hyde C, Wake B, Bryan S, Barton P, Fry-Smith A, Davenport C et al. Fludarabine as second-line therapy for B cell lymphocytic leukaemia: a technology assessment. Health Technol Assess 2002;6(2). https://doi.org/10.3310/hta6020
DOI:

https://doi.org/10.3310/hta6020